Travatan Z is a drug owned by Sandoz Inc. It is protected by 5 US drug patents filed in 2013. Out of these, 3 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 13, 2029. Details of Travatan Z's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8268299 | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(4 years from now) | Active |
| US8323630 | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(2 years from now) | Active |
| US8388941 | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(2 years from now) | Active |
| US5889052 | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(9 years ago) |
Expired
|
| US5510383 | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Travatan Z's patents.
Latest Legal Activities on Travatan Z's Patents
Given below is the list of recent legal activities going on the following patents of Travatan Z.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 May, 2024 | US8323630 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Mar, 2024 | US8268299 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Aug, 2020 | US8388941 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 May, 2020 | US8323630 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Mar, 2020 | US8268299 (Litigated) |
| Review Certificate Mailed | 11 Jun, 2019 | US8268299 (Litigated) |
| Review Certificate | 02 May, 2019 | US8268299 (Litigated) |
| Termination or Final Written Decision | 20 Sep, 2018 | US8268299 (Litigated) |
| Request for Trial Granted Critical | 22 Sep, 2017 | US8268299 (Litigated) |
| Petition Entered | 28 Mar, 2017 | US8268299 (Litigated) |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Travatan Z and ongoing litigations to help you estimate the early arrival of Travatan Z generic.
Travatan Z's Litigations
Travatan Z been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2013, against patent number US8388941. The petitioner Apotex Corp., challenged the validity of this patent, with Alcon Research, Ltd. as the respondent. Click below to track the latest information on how companies are challenging Travatan Z's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8268299 | March, 2017 |
FWD Entered
(20 Sep, 2018) | Alcon Research, Ltd. | Argentum Pharmaceuticals LLC |
| US8268299 | July, 2013 |
Terminated-Settled
(21 Jul, 2014) | ALCON RESEARCH, LTD. | Apotex Corp. |
| US8323630 | July, 2013 |
Terminated-Settled
(21 Jul, 2014) | ALCON RESEARCH, LTD. | Apotex Corp. |
| US8388941 | July, 2013 |
Terminated-Settled
(21 Jul, 2014) | Alcon Research, Ltd. | Apotex Corp. |
Several oppositions have been filed on Travatan Z's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Travatan Z's generic, the next section provides detailed information on ongoing and past EP oppositions related to Travatan Z patents.
Travatan Z's Oppositions Filed in EPO
Travatan Z has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 02, 2012, by Allergan, Inc.. This opposition was filed on patent number EP07842914A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP07842925A | Mar, 2016 | Pohlman, Sandra M. | Patent maintained as amended |
| EP07842914A | Aug, 2012 | Pohlman, Sandra M. | Patent maintained as amended |
| EP07842914A | Aug, 2012 | ALLERGAN, INC. | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Travatan Z is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Travatan Z's family patents as well as insights into ongoing legal events on those patents.
Travatan Z's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Travatan Z's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 13, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Travatan Z Generic API suppliers:
Travoprost is the generic name for the brand Travatan Z. 8 different companies have already filed for the generic of Travatan Z, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Travatan Z's generic
How can I launch a generic of Travatan Z before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Travatan Z's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Travatan Z's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Travatan Z -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.00004 | 19 Feb, 2009 | 1 | 02 Dec, 2014 | Extinguished |
Alternative Brands for Travatan Z
Travatan Z which is used for reducing intraocular pressure in glaucoma and ocular hypertension., has several other brand drugs in the same treatment category and using the same active ingredient (Travoprost). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Alcon Pharms Ltd |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Travoprost. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Travoprost, Travatan Z's active ingredient. Check the complete list of approved generic manufacturers for Travatan Z
About Travatan Z
Travatan Z is a drug owned by Sandoz Inc. It is used for reducing intraocular pressure in glaucoma and ocular hypertension. Travatan Z uses Travoprost as an active ingredient. Travatan Z was launched by Sandoz in 2006.
Approval Date:
Travatan Z was approved by FDA for market use on 21 September, 2006.
Active Ingredient:
Travatan Z uses Travoprost as the active ingredient. Check out other Drugs and Companies using Travoprost ingredient
Treatment:
Travatan Z is used for reducing intraocular pressure in glaucoma and ocular hypertension.
Dosage:
Travatan Z is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.004% | SOLUTION/DROPS | Prescription | OPHTHALMIC |